Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    "Choroiditis"
Show Display Options
Rank Status Study
1 Completed Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
Conditions: Vogt Koyanagi Harada Disease;   Serpiginous Choroiditis;   Multifocal Choroiditis
Interventions: Drug: Bevacizumab;   Procedure: Intravitreal Injection of Bevacizumab
2 Completed Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
Conditions: Neovascularization;   Tuberculosis;   Multifocal Serpiginous Choroiditis;   Harada Toxoplasmosis
Intervention:
3 Completed Evaluation and Treatment of Patients With Inflammatory Eye Diseases
Conditions: Choroiditis;   Iridocyclitis;   Iritis;   Retinal Disease
Intervention:
4 Withdrawn Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Conditions: Choroidal Neovascularization;   Myopia;   Punctate Inner Choroidopathy (PIC);   Multifocal Choroiditis;   Ocular Histoplasmosis Syndrome;   Central Serous Chorioretinopathy (CSC);   Angioid Streaks;   Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.);   Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
5 Completed Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Conditions: Coats' Disease;   Idiopathic Retinal Telangiectasia;   Retinal Angiomatous Proliferation;   Polypoidal Choroidal Vasculopathy;   Pseudoxanthoma Elasticum;   Pathological Myopia;   Multi-focal Choroiditis;   Rubeosis Iridis;   Von Hippel Lindau Disease;   BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Intervention: Drug: ranibizumab injection (0.5 mg)
6 Not yet recruiting Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Conditions: Uveitis;   Uveitis, Posterior;   Uveitis, Anterior;   Uveitis, Intermediate;   Panuveitis
Intervention:
7 Recruiting A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye
Conditions: Posterior Uveitis;   Intermediate Uveitis;   Panuveitis
Intervention: Drug: FAI insert
8 Recruiting Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis
Conditions: Posterior Uveitis;   Intermediate Uveitis;   Panuveitis
Interventions: Drug: Sham Injection;   Drug: FAI Insert
9 Completed Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
Conditions: Uveitis;   Intermediate Uveitis;   Posterior Uveitis;   Panuveitis;   Noninfectious Uveitis
Intervention: Drug: triamcinolone acetonide (Triesence®)
10 Active, not recruiting Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
Conditions: Intermediate Uveitis;   Posterior Uveitis;   Pan-uveitis
Intervention: Drug: Tocilizumab
11 Active, not recruiting Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
Conditions: Posterior Uveitis;   Intermediate Uveitis;   Panuveitis
Interventions: Drug: FAI insert;   Drug: Sham injection
12 Recruiting Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
Conditions: Non-infectious Intermediate Uveitis;   Non-infectious Posterior Uveitis;   Non-infectious Panuveitis
Interventions: Drug: LFG316;   Drug: Conventional Therapy
13 Recruiting Intravitreal Sirolimus as Therapeutic Approach to Uveitis
Conditions: Uveitis;   Intermediate Uveitis;   Posterior Uveitis;   Panuveitis
Interventions: Drug: Intravitreal injection 440mcg;   Drug: Intravitreal injection of sirolimus 880mcg
14 Unknown  Sirolimus as Therapeutic Approach to Uveitis
Conditions: Uveitis;   Intermediate Uveitis;   Posterior Uveitis;   Panuveitis
Intervention: Drug: Sirolimus (rapamycin)
15 Completed A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
Conditions: Uveitis, Posterior;   Uveitis, Intermediate;   Panuveitis
Interventions: Drug: Placebo;   Drug: LX211
16 Completed A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
Conditions: Uveitis, Posterior;   Uveitis, Intermediate;   Panuveitis
Interventions: Drug: Placebo;   Drug: LX211
17 Terminated Safety and Preliminary Efficacy Study of V404 PDS in Uveitis
Conditions: Uveitis, Posterior;   Uveitis, Intermediate
Intervention: Drug: V404
18 Recruiting Study of the Effectiveness of Ozurdex for the Control of Uveitis
Conditions: Uveitis, Intermediate;   Uveitis, Posterior
Intervention: Drug: Dexamethasone pellet
19 Not yet recruiting Safety &Efficacy of CF101 to Subjects With Uveitis
Conditions: Uveitis, Posterior;   Uveitis, Intermediate
Interventions: Drug: CF101;   Drug: Placebo
20 Completed Retisert and Cataract Surgery in Patients With Severe Uveitis
Conditions: Intermediate Uveitis;   Posterior Uveitis
Intervention: Device: Retisert (fluocinolone acetonide implant)

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.